KalVista Pharmaceuticals, Inc. expects to complete enrollment for the KVD900 Phase 2 clinical trial before year-end 2019 and to provide data in 2020.
“We are pleased with the rate of enrollment of our Phase 2 clinical trial of KVD900 in HAE patients,” said Andrew Crockett, CEO of KalVista. “Our plan to recruit patients primarily in European HAE centers is serving us well, with good recruitment at our clinical sites. Regulatory and ethical approvals have been timely, although start-up at several sites has taken longer than anticipated. We have identified a robust pipeline of patients eager to try a potentially efficacious oral on-demand treatment, and we anticipate that we will complete recruitment before year-end 2019 and provide data in 2020.”
(Source: KalVista)
